Skip to content
Screener

ADMA Biologics ADMA Q4 2025 Annual earnings

Reported February 25, 2026 · After market close

Revenue$139.2MMiss by $437.0K
EPS$0.20Beat by $0.02
Revenue estimate$139.6M
EPS estimate$0.19

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$138.1M
EPS estimate$0.19

Financials

Q4 2025

Income statement

See full
Revenue$139.2M+18.4%
Gross profit$88.8M+40.2%
Operating income$62.8M+63.7%
Net income$49.4M-55.9%
EPS (diluted)$0.20-56.5%

Balance sheet

See full
Cash & equivalents$87.6M-15.0%
Total debt$79.8M-2.8%
Total equity$477.3M+36.8%
Total assets$624.2M+27.7%

Cash flow

See full
Operating cash flow$35.6M-29.0%
CapEx$1.1M-60.7%
Free cash flow$34.6M-27.2%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$4.34B+7.1%
Enterprise value$4.33B+7.4%
P/E29.5×+9.0×
P/S8.5×-1.0×

Profitability

See full
Gross margin57.4%+5.9pp
Operating margin37.5%+4.9pp
Net margin28.8%-17.6pp
FCF margin5.5%-20.4pp

Returns & leverage

See full
Return on equity35.6%-46.1pp
Debt / equity0.2×-0.1×
Current ratio6.7×+0.7×

Segments

By segment

See full
ADMA Bio Manufacturing$123.3M+10.1%
Plasma Collection Centers$16.0M+179%

By geography

See full
US$137.4M+19.8%

FAQ

When did ADMA Biologics report Q4 2025 earnings?
ADMA Biologics (ADMA) reported Q4 2025 earnings on February 25, 2026 after market close.
What were ADMA Biologics's Q4 2025 revenue and EPS?
ADMA Biologics reported revenue of $139.2M and eps of $0.20 for Q4 2025.
Did ADMA Biologics beat estimates in Q4 2025?
Revenue missed the consensus estimate of $139.6M by $437.0K. EPS beat the consensus estimate of $0.18 by $0.02.
How did ADMA Biologics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 18.4% from $117.5M a year earlier and eps grew 42.9% from $0.14.
Where can I find ADMA Biologics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001140361-26-006781) and the 10-K periodic report (0001140361-26-006815) directly on SEC EDGAR. The filing index links above go to sec.gov.